PMID: 9548227Apr 21, 1998Paper

Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group

Seizure : the Journal of the British Epilepsy Association
M BaulacJ J Portal

Abstract

The objectives were to evaluate gabapentin add-on therapy in a large population under conditions close to real practice and to determine the therapeutic doses as reached with adaptable dosages. A 6-month multicentre, open-label study, involved addition of gabapentin to pre-existing treatment at the initial dosage of 1200 mg and subsequent adjustment between 900 and 2400 mg/day according to efficacy and tolerability. A study group of 610 adult patients, with partial epilepsy, persistent seizures and a median seizure frequency with a baseline of 7.2 per month were recruited; one-third had less than four seizures per month. Polypharmacy was frequent, with a mean of 2.3 concomitant drugs. After 6 months, 368 patients (62%) continued on gabapentin, at a mean dosage of 1739 mg/day with 44% of responders. On an intention-to-treat basis, median reduction in frequency was 21.2%, and the responder rate was 33.9%. The responder rate increased to 40.7% in the less severe subgroup receiving only one concomitant drug. Seventy-nine patients (13.4%) remained without seizures during the last evaluation period, versus nine (1.5%) during the baseline. Most of them had initially less than four seizures per month. The most frequent adverse effects,...Continue Reading

References

Nov 1, 1992·Epilepsy Research·L M OjemannJ Wallace
Jun 1, 1987·Journal of Neurology, Neurosurgery, and Psychiatry·P CrawfordD Chadwick
Sep 1, 1995·Seizure : the Journal of the British Epilepsy Association·C D Binnie
May 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·C Short, L Cooke
Jan 8, 1994·Lancet·D Chadwick
Jan 1, 1996·Annals of Neurology·O A PetroffR H Mattson
Jun 13, 1996·The New England Journal of Medicine·M A Dichter, M J Brodie
Dec 1, 1996·Baillière's Clinical Neurology·E A Wilson, M J Brodie

❮ Previous
Next ❯

Citations

Apr 3, 1999·Medicinal Research Reviews·J S Bryans, D J Wustrow
Dec 4, 2003·Epilepsy Research·Barry E GidalAnne-Francoise Herbeuval
Jul 18, 2003·Clinical Therapeutics·Michael J McLean, Barry E Gidal
Jun 18, 1999·Epilepsy Research·C B DodrillM W Pierce
Oct 26, 1999·Epilepsia·G L Morris
Nov 14, 2014·CNS Drugs·J van GaalenB P C van de Warrenburg
Dec 25, 2015·Current Gastroenterology Reports·Valentina MediciKeith R Miller
Apr 7, 2010·Journal of Pharmaceutical and Biomedical Analysis·Laura MercoliniMaria Augusta Raggi
Jul 31, 2007·Journal of Pain and Symptom Management·Neil A HagenUNKNOWN Canadian Tetrodotoxin Study Group
May 24, 2008·Acta Psychiatrica Scandinavica·C TorrentE Vieta
Dec 7, 2013·Expert Review of Clinical Pharmacology·Joseph ChukwuGianpiero L Cavalleri
Nov 10, 2005·The Annals of Pharmacotherapy·Margaret Malone
Dec 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·P Jallon, F Picard
Nov 24, 2005·Family Practice·John BushnellUNKNOWN MaGPIe Research Group
Jul 15, 2020·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Maryam SafahaniAli A Asadi-Pooya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.